ArticleAmerican journal of translational research2026
Mannitol plus pilocarpine for primary acute angle-closure glaucoma: efficacy and safety analysis.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo retrospectively analyze the efficacy and safety of mannitol (MAN) combined with pilocarpine (PC) in patients with primary acute angle-closure glaucoma (PAACG).
methodsA total of 103 PAACG patients were retrospectively enrolled and assigned to either the control group (PC alone) or the research group (MAN + PC). Treatment response, safety profiles, intraocular pressure (IOP), visual acuity (VA), hemodynamic parameters (end diastolic velocity [EDV], peak systolic velocity [PSV], and resistance index [RI]), anxiety/depression, and quality of life (Short-Form 36-Item Health Survey [SF-36]) were compared between the two groups. Furthermore, factors potentially associated with therapeutic efficacy and safety were analyzed.
resultsThe overall response rate was significantly higher in the research group than in the control group, whereas the incidence of adverse events were comparable between the two groups. After treatment, patients in the research group showed markedly lower IOP, PSV RI, and anxiety and depression scores, as well as significantly higher VA, EDV, and SF-36 scores, compared with the control group. However, none of these variables were independently associated with treatment efficacy or safety.
conclusionMAN combined with PC is an effective and safe therapeutic strategy for PAACG patients. This combination therapy can improve patients' quality of life, reduce IOP, enhance VA, and improve central retinal artery hemodynamics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.